Compare the effect of clonidine and tizanidine in controlling pain after lumbar fusion surgery

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210904052371N1

Enrollment

Registered

2021-10-19

Start date

2019-07-16

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain control after cesarean section. Other acute postprocedural pain

Interventions

Intervention 1: Intervention group: Clonidine. Intervention 2: Intervention group: tizanidine. Intervention 3: Control group: Plasbo.

Eligibility

Sex/Gender

All

Age

35 Years to 70 Years

Inclusion criteria

Inclusion criteria: Confirm the diagnosis by physical examination, CT scan and MRI The patient's desire to participate in the study and gain informed consent Candidate for non-emergency lumbar fusion surgery Age between 70-35 years and No history of tizanidine allergy Absence of bradycardia (HR <60) in patients Absence of CNS disease No history of any previous back surgery

Exclusion criteria

Exclusion criteria: The patient's unwillingness to continue participating in the study at any time Taking narcotic painkillers 24 hours before the intervention Alcohol or drug abuse Occurrence of any unusual complication during surgery

Design outcomes

Primary

Measure	Time frame
Intensity of patients' pain. Timepoint: 48 hours. Method of measurement: Visual Analogue Scale.;The amount of drugs used. Timepoint: 48 hours. Method of measurement: Visual Analogue Scale.	—

Secondary

Measure	Time frame
The rate of nausea. Timepoint: 48 hours. Method of measurement: Visual Analogue Scale.;The rate of vomiting. Timepoint: 48 hours. Method of measurement: Visual Analogue Scale.;Itching rate. Timepoint: 48 hours. Method of measurement: Visual Analogue Scale.;Dry mouth. Timepoint: 48 hours. Method of measurement: Visual Analogue Scale.;Bradycardia rate. Timepoint: 48 hours. Method of measurement: Visual Analogue Scale.;Headache rate. Timepoint: 48 hours. Method of measurement: Visual Analogue Scale.;Vertigo. Timepoint: 48 hours. Method of measurement: Visual Analogue Scale.;The rate of drowsiness. Timepoint: 48 hours. Method of measurement: Visual Analogue Scale.	—

Measure

Time frame

The rate of nausea. Timepoint: 48 hours. Method of measurement: Visual Analogue Scale.;The rate of vomiting. Timepoint: 48 hours. Method of measurement: Visual Analogue Scale.;Itching rate. Timepoint: 48 hours. Method of measurement: Visual Analogue Scale.;Dry mouth. Timepoint: 48 hours. Method of measurement: Visual Analogue Scale.;Bradycardia rate. Timepoint: 48 hours. Method of measurement: Visual Analogue Scale.;Headache rate. Timepoint: 48 hours. Method of measurement: Visual Analogue Scale.;Vertigo. Timepoint: 48 hours. Method of measurement: Visual Analogue Scale.;The rate of drowsiness. Timepoint: 48 hours. Method of measurement: Visual Analogue Scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGoli Azzi

Mazandaran University of Medical Sciences

Gaezi@mazums.ac.ir+98 11 3336 1700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026